Compound · clinical trials

Crisugabalin clinical trials

Also listed in trial records as HSK16149

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our China register that name Crisugabalin as an intervention. Synced 10 Nov 2026

6Current trials

4Recruiting now

6Lead sponsors

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Crisugabalin is named as an intervention in 6 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Guangdong Provincial People's Hospital (1). The most-studied condition is Neuropathic Pain.

How Crisugabalin works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

Neuropathic painPhase 3
Postherpetic neuralgiaPhase 3
Generalized anxiety disorderPhase 2
Head and neck cancerPhase 2
Herpes zosterPhase 2
Restless legs syndromePhase 1

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314958, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13764, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Crisugabalin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting467%
Not yet open117%
Active, closed117%

Trials by phase

Phase 4233%
Phase 2233%
Not applicable117%
Phase 1117%

Clinical trials of Crisugabalin

6 trials

Study	Phase	Status	Lead sponsor	Registers
Crisugabalin for Radiotherapy-Related Neuropathic Pain NCT06766916 · ClinicalTrials.gov ↗ · Neuropathic Pain	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder NCT07330648 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder	Phase 2	Recruiting	Anhui Medical University	China
Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety NCT07453862 · ClinicalTrials.gov ↗ · Restless Leg Syndrome (RLS), Variant Restless Legs Syndrome	Phase 1	Recruiting	Beijing Friendship Hospital	China
The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia NCT07196657 · ClinicalTrials.gov ↗ · Fibromyalgia, Pregabalin, Pain	Not applicable	Recruiting	Beijing Tiantan Hospital	China
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial NCT07699770 · Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain	Phase 4	Not yet open	Tang-Du Hospital	China
EFficacy and safEty of cRisugabalin on nocipLastic paIn in Patients With Parkinson's Disease (RELIEF-PD): a Multicentre, Double-blind, Randomised Controlled Trial NCT07483398 · ClinicalTrials.gov ↗ · PARKINSON DISEASE (Disorder)	Phase 4	Active, closed	Guangdong Provincial People's Hospital	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Crisugabalin

9 conditions

Neuropathic Pain2 PARKINSON DISEASE (Disorder)1 Fibromyalgia1Pregabalin1Pain1 Generalized Anxiety Disorder1Neuromyelitis Optica Spectrum Disorders (NMOSD)1Restless Leg Syndrome (RLS)1Variant Restless Legs Syndrome1

By country register

Register	Trials	Recruiting
Clinical trials in China	6	4

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Crisugabalin trials

How many clinical trials are testing Crisugabalin?

6 current trials in our China register name Crisugabalin (also registered as HSK16149) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Crisugabalin trials recruiting patients?

Yes. 4 of the 6 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Crisugabalin clinical trials?

Guangdong Provincial People's Hospital (1), Beijing Tiantan Hospital (1), Anhui Medical University (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Crisugabalin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Crisugabalin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crisugabalin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.